Researchers at Fred Hutch Cancer Center have found in pre-clinical studies that an experimental gene therapy for genital and oral herpes removed 90% or more of the infection and suppressed how much ...
The progress of EDIT-301 in Phase 1/2 RUBY and EdiTHAL studies is encouraging. I am increasingly turning more bearish on EDIT due to increased competition and a less attractive financial outlook. The ...
Sizable investments. High-profile appearances at industry events. Unique development platforms. These elements would augur well for companies of any kind—and companies hoping to bring epigenome ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Editas Medicine (NASDAQ:EDIT) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, 2025, Clear Street raised its price target on Editas Medicine (NASDAQ:EDIT) to ...
Editas Medicine reported promising initial results from the EDIT-301 trials for inherited blood disorders, leading to a rating upgrade to "outperform" by Raymond James. The company's financial ...
CAMBRIDGE, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly ...
Intellia Therapeutics NTLA reported second-quarter results in line with our expectations, and its pipeline candidates are continuing to progress in development. Collaboration revenue totaled $13.6 ...
CRISPR Therapeutics CRSP reported third-quarter results in line with our expectations, and its pipeline candidates are continuing to make progress. We maintain our positive outlook and fair value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results